Mounjaro side effects: 18 percent had nausea at 15 mg
Nausea ran 12 percent at Mounjaro 5 mg, 15 percent at 10 mg and 18 percent at 15 mg, against 4 percent on placebo. The clinical trials enrolled adults with type 2 diabetes. Gut reactions of any kind climbed from 37.1 to 43.6 percent across the same three doses. GLP Chart read the FDA label on DailyMed, revised August 2026.
| Reaction | Placebo (n=235) | 5 mg (n=237) | 10 mg (n=240) | 15 mg (n=241) |
|---|---|---|---|---|
| Nausea | 4% | 12% | 15% | 18% |
| Diarrhea | 9% | 12% | 13% | 17% |
| Decreased appetite | 1% | 5% | 10% | 11% |
| Vomiting | 2% | 5% | 5% | 9% |
| Constipation | 1% | 6% | 6% | 7% |
| Dyspepsia (indigestion) | 3% | 8% | 8% | 5% |
| Abdominal pain (stomach pain) | 4% | 6% | 5% | 5% |
This curve climbs, and the Zepbound one does not
Nausea rises with every step here: 12 percent at 5 mg, 15 percent at 10 mg, 18 percent at 15 mg. Gut reactions of any kind rise the same way, from 37.1 to 43.6 percent, against 20.4 percent on placebo.
The same molecule on the Zepbound label does not do that. Nausea peaks there at the middle dose. Constipation falls as the dose climbs. The clinical trials behind the two tables enrolled different people.
Read the diarrhea row before you compare anything. It reads 17 percent at 15 mg against 9 percent on placebo, so more than half of that rate showed up in people taking nothing.
Who stopped and why
The label breaks out the exits over gut reactions. 3 percent stopped at 5 mg, 5.4 percent at 10 mg and 6.6 percent at 15 mg, against 0.4 percent on placebo.
Reactions the label calls severe ran 1.3 percent at 5 mg, 0.4 percent at 10 mg and 1.2 percent at 15 mg, against 0.9 percent on placebo. That row does not climb with the dose. The 10 mg arm was the lowest of the four.
On timing the label says: The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time.
No week number, no share of patients.
The cash market sells Zepbound instead
Mounjaro is prescribed for blood sugar, and the cash telehealth market sells the drugs approved for weight loss. So the tirzepatide with a published cash price is Zepbound or a compounded version. Switching because of side effects usually means changing drug, not just dose.
What the dose does to your bill
LillyDirect prices Zepbound by dose. Every step it publishes, checked August 31, 2026.
| Dose | Cost / mo |
|---|---|
| Zepbound vial, starter dose (2.5mg) | $299/mo |
| Zepbound vial, maintenance (5mg) | $399/mo |
| Zepbound vial, higher doses (7.5mg+) | $449/mo |
| Program | At the dose you stay on | At the top dose it publishes |
|---|---|---|
| CVS MinuteClinic | $428/mo | $528/mo |
| Walgreens Weight Management | $448/mo | $548/mo |
| LifeMD | $498/mo | $698/mo |
| Ro Body | $548/mo | $598/mo |
| Hims & Hers | $598/mo | Not published |
Each figure is the total a month, membership and fees in, read off the program's own published pricing. A program that publishes no Zepbound price is not listed. See every price we track.
Compare every tirzepatide route at its maintenance price →
The label has no advice for a bad week
Zepbound's label tells a prescriber to consider a lower maintenance dose when a patient does not tolerate one. Mounjaro's says nothing of the kind. Every step up is written as conditional on needing more glycemic control, after at least four weeks on the current dose.
So a hold on this label is a conversation you start. Four weeks is the floor between steps. There is no ceiling on how long you stay.
One warning is attached to the reactions themselves. Dehydration from vomiting or diarrhea has caused kidney injury, so fluids are what to watch. Call the same day for severe stomach pain reaching your back, vomiting that stops you drinking for a day, or yellow skin or eyes. The triage list on the pillar page carries the rest.
Frequently asked questions
What are the most common Mounjaro side effects?
Nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and stomach pain. At 15 mg they read 18, 17, 11, 9, 7, 5 and 5 percent. Those 7 rows are the whole table, because the label only lists a reaction that reached 5 percent.
Does a higher Mounjaro dose mean more side effects?
On this label, mostly yes. Nausea climbs from 12 percent at 5 mg to 18 percent at 15 mg and decreased appetite from 5 to 11 percent. Gut reactions of any kind climb from 37.1 to 43.6 percent. Indigestion is the exception and falls at the top dose.
Why does Mounjaro read lower than Zepbound for the same drug?
Two reasons, both on the labels. The clinical trials enrolled different people: adults with type 2 diabetes rather than adults with obesity. And the tables use different cuts, 5 percent here against 2 percent on Zepbound, so Mounjaro prints 7 rows and Zepbound prints 16.
How many people stop Mounjaro because of side effects?
The label breaks out the gut-reaction exits: 3 percent at 5 mg, 5.4 percent at 10 mg and 6.6 percent at 15 mg, against 0.4 percent on placebo. Reactions it calls severe ran 1.3 to 1.2 percent against 0.9 percent.
Do Mounjaro side effects get better?
The label says: The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time. It puts no week number on that and gives no share of patients.
What does Mounjaro cost without insurance?
The cash telehealth market sells the drugs approved for weight loss, which is Zepbound or compounded tirzepatide. Both are priced in the table above.
Every dosage sentence on this page is written to a prescriber, not to you. Holding a dose, dropping back or stopping changes what the drug is doing. Take the label language to the appointment.
Sources
Evidence checked August 31, 2026
Every figure above is taken from the document beside it, the FDA label or the trial that produced it, so you can read the source instead of trusting us. No clinician reviews these pages. What that means.
- Every rate in the Mounjaro table, the 43.6 percent gastrointestinal figure, the discontinuation figures and the dose-escalation ruleFDA prescribing information for Mounjaro (DailyMed, revised August 2026)
- The Zepbound comparison, including 29 percent nausea at 10 mg in adults with obesity or overweightFDA prescribing information for Zepbound (DailyMed, revised August 2026)
